Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Su Young Chae

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Biomaterials|February 13, 2010
Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetesJi-Hyun Kong, Eun Ju Oh, Su Young Chae, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 17, 2009
Controlled release of insulin from pH/temperature-sensitive injectable pentablock copolymer hydrogelDai Phu Huynh, Guang Jin Im, Su Young Chae, et al.
Journal of Medicinal Chemistry|October 2, 2008
Conjugated chitosan as a novel platform for oral delivery of paclitaxelEunhye Lee, Jinju Lee, In-Hyun Lee, et al.
The Journal of Physical Chemistry. B|May 24, 2013
Effect of arginine-rich peptide length on the structure and binding strength of siRNA-peptide complexesMinwoo Kim, Hyun Ryoung Kim, Su Young Chae, et al.
Bioconjugate Chemistry|December 15, 2007
Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral deliverySu Young Chae, Cheng-Hao Jin, Han Jong Shin, et al.
Regulatory Peptides|October 28, 2008
Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agentKang Choon Lee, Su Young Chae, Tae Hyung Kim, et al.
Biochemical Pharmacology|October 24, 2006
Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stabilityYu Seok Youn, Su Young Chae, Seulki Lee, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 23, 2010
The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeuticsSu Young Chae, Yang Gyu Choi, Sohee Son, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|October 2, 2007
Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluationYu Seok Youn, Su Young Chae, Seulki Lee, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 21, 2007
Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selectionYu Seok Youn, Min Jung Kwon, Dong Hee Na, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Biomaterials|February 13, 2010
Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetesJi-Hyun Kong, Eun Ju Oh, Su Young Chae, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 17, 2009
Controlled release of insulin from pH/temperature-sensitive injectable pentablock copolymer hydrogelDai Phu Huynh, Guang Jin Im, Su Young Chae, et al.
Journal of Medicinal Chemistry|October 2, 2008
Conjugated chitosan as a novel platform for oral delivery of paclitaxelEunhye Lee, Jinju Lee, In-Hyun Lee, et al.
The Journal of Physical Chemistry. B|May 24, 2013
Effect of arginine-rich peptide length on the structure and binding strength of siRNA-peptide complexesMinwoo Kim, Hyun Ryoung Kim, Su Young Chae, et al.
Bioconjugate Chemistry|December 15, 2007
Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral deliverySu Young Chae, Cheng-Hao Jin, Han Jong Shin, et al.
Regulatory Peptides|October 28, 2008
Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agentKang Choon Lee, Su Young Chae, Tae Hyung Kim, et al.
Biochemical Pharmacology|October 24, 2006
Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stabilityYu Seok Youn, Su Young Chae, Seulki Lee, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 23, 2010
The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeuticsSu Young Chae, Yang Gyu Choi, Sohee Son, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|October 2, 2007
Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluationYu Seok Youn, Su Young Chae, Seulki Lee, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 21, 2007
Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selectionYu Seok Youn, Min Jung Kwon, Dong Hee Na, et al.
Pageof 5